Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Thrombosis and Haemostasis

• Publication date

  2005-07-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1160/TH04-08-0497PMID 16113828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In-Depth Haplotype Analysis of ABCA1 Gene Polymorphisms in Relation to Plasma ApoA1 Levels and Myocardial Infarction

  2004cited by this paper
• Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays

  2004cited by this paper
• Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor

  2004cited by this paper
• A new algorithm for haplotype‐based association analysis: the Stochastic‐EM algorithm

  2004cited by this paper
• Development of a Genotype 325–Specific proCPU/TAFI ELISA

  2003cited by this paper
• Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme*

  2002cited by this paper
• Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms

  2001cited by this paper
• Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.

  2001cited by this paper
• A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels.

  2001cited by this paper
• Immunological Assay for the Determination of Procarboxypeptidase U Antigen Levels in Human Plasma

  2001cited by this paper
• Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.

  2001cited by this paper
• Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor*

  2000cited by this paper
• Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors

  2000cited by this paper
• Plasma TAFI Antigen Variations in Healthy Subjects

  2000cited by this paper
• Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B).

  1999cited by this paper
• Identification and Characterization of Two Thrombin-activatable Fibrinolysis Inhibitor Isoforms

  1998cited by this paper
• Activation of Thrombin-activable Fibrinolysis Inhibitor Requires Epidermal Growth Factor-like Domain 3 of Thrombomodulin and Is Inhibited Competitively by Protein C*

  1998cited by this paper
• Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of Coagulation

  1998cited by this paper
• Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties*

  1998cited by this paper
• Activated Human Plasma Carboxypeptidase B Is Retained in the Blood by Binding to α2-Macroglobulin and Pregnancy Zone Protein*

  1996cited by this paper
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex*

  1996cited by this paper
• The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.

  1996cited by this paper
• Activation and characterization of procarboxypeptidase B from human plasma.

  1995cited by this paper
• Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma.

  1991cited by this paper
• Testing for association between disease and linked marker loci: a log-linear-model analysis.

  1991cited by this paper
• Characterisation of a Carboxypeptidase in Human Serum Distinct from Carboxypeptidase N

  1989cited by this paper
• A simple salting out procedure for extracting DNA from human nucleated cells.

  1988cited by this paper
• A novel , possibly functional , single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor ( TAFI ) gene is also associated with TAFI levels

  year unknowncited by this paper

• Association of Carboxypeptidase B2 Gene Polymorphisms With Graft Loss in Kidney Transplantation

  2026cites this paper
• Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes

  2023cites this paper
• Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme

  2023cites this paper
• Measuring Fibrinolysis

  2021cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review

  2021cites this paper
• TafiIn Fibrinolysis-A Review

  2020cites this paper
• Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?: JACC Review Topic of the Week.

  2019cites this paper
• A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor

  2018cites this paper
• Measuring fibrinolysis: from research to routine diagnostic assays

  2018cites this paper
• Protein Z , a protein seeking a pathology

  2017cites this paper
• Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis

  2017cites this paper
• Changes in thrombin activatable fibrinolysis inhibitor and its role in normal pregnancy and pre-eclampsia

  2017cites this paper
• Phenotypic Heterogeneity of Hemostasis in Severe Hemophilia

  2015cites this paper
• Thrombin‐activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis

  2015cites this paper
• Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR

  2015cites this paper
• The role of coagulation factor XII in fibrin clot formation and fibrinolysis

  2014cites this paper
• Regulation of expression of CPB2, the gene encoding human thrombin activatable fibrinolysis inhibitor (TAFI): the role for post-transcriptional regulation

  2014cites this paper
• activatable fibrinolysis inhibitor antigen levels by a trans-ethnic study Fine mapping of quantitative trait nucleotides underlying thrombin

  2013cites this paper
• Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone

  2013cites this paper
• Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 3′‐untranslated region

  2012cites this paper
• Thrombin-activatable fibrinolysis inhibitor and bacterial infections

  2011cites this paper
• Comparative study of commercially available procarboxypeptidase U (thrombin‐activatable fibrinolysis inhibitor) assays

  2011cites this paper
• An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.

  2011cites this paper
• Novel Insights into Genetics of Arterial Thrombosis

  2011cites this paper
• Regulation of the Gene Encoding Thrombin-Activable Fibrinolysis Inhibitor in Non-Hepatic Cells

  2011cites this paper
• Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells

  2011cites this paper
• The role of the fibrinolytic system in arterial and venous thrombosis

  2010cites this paper
• The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study 1

  2009cites this paper
• Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.

  2009cites this paper
• Protein Z, a protein seeking a pathology

  2008cites this paper
• TAFI antigen level variability in young healthy Asian Indians; first report from Asia.

  2008cites this paper
• A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels

  2008cites this paper
• Thrombin activatable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian‐Indian population but may not be a risk for stroke

  2008cites this paper
• The Phenotypic Heterogeneity of Severe Hemophilia

  2008cites this paper
• The phenotypic heterogeneity of severe hemophilia.

  2008cites this paper
• Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis

  2008cites this paper
• Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis.

  2008cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation

  2007cites this paper
• Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors

  2007cites this paper
• Fibrinolysis and the risk of venous and arterial thrombosis

  2007cites this paper
• Das TAFI-System

  2007cites this paper
• Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.

  2007cites this paper
• A role for procarboxypepidase U (TAFI) in thrombosis.

  2007cites this paper
• The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer

  2007cites this paper
• Molecular analysis of the human thrombin‐activatable fibrinolysis inhibitor gene promoter

  2007cites this paper
• Evolution of Thrombin Formation and Fibrinolysis Markers, Including Thrombin-Activatable Fibrinolysis Inhibitor, during Severe Meningococcemia

  2006cites this paper
• Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis

  2006cites this paper
• Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasmaTAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD)

  2006cites this paper
• Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study.

  2006cites this paper
• TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study

  2005cites this paper
• Genetic association studies.

  2005cites this paper